Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | DOI: 10.5507/bp.2024.036
Association of biomarkers of cardiac remodeling, myocardial fibrosis and inflammation with parameters of heart function and structure in patients with arterial hypertension
- 1 Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic
- 2 Cardiovascular Center, Na Homolce Hospital, Prague, Czech Republic
- 3 Laboratory of Cellular and Molecular Immunology, Institute of Microbiology, Academy of Sciences, Prague, Czech Republic
- 4 Department of Medical Biophysics and Medical Informatics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
Backround and Aims. Early evaluation of cardiac remodeling may be useful in predicting heart failure in patients with arterial hypertension. The identification of biomarkers as useful clinical tools in this regard is ongoing. The aim of this study was to evaluate the association of selected cardiac biomarkers levels with parameters of cardiac structure and function in patients with arterial hypertension.
Patients and Methods: Included in the study were patients with arterial hypertension with normal left ventricular ejection fraction (LV EF) and absence of signs of heart failure. The levels of selected biomarkers: NT-proBNP, sST2, Galectin-3, GDF-15, Cystatin C, TIMP-1 and ceruloplasmin were measured and assessed together with other biochemical and echocardiographic parameters.
Results: A total of 92 patients (61% men) mean age 61.5 years were included. Mean LV EF was 64.7% and mean LV mass index was 91.7 g/m2. NT-proBNP level correlated significantly with the parameters of LV diastolic function: velocity of E wave (r=0.377, P<0.002), and with E/A ratio, (r=0.455, P<0.0001), with E lat (r=-0.354, P=0.006), E/E' ratio, r=0.393, P<0.002, with ePAP (r=0.390, P=0.014), and with age (r=0.384, P<0.0001). Statistically significant correlations for GDF-15 were as follows: with age (r=0.426, P<0.0001) and left atrial diameter (LA) (r=0.401, P<0.0001), for Cystatin C there are statistically significant correlation with age (r=0.288, P=0.006) and LA (r=0.329, P=0.004). Only sST2 level correlated significantly with parameters of cardiac structure: with LV mass (r=0.290, P<0.01) and LV mass index (r=0.307, P=0.012) and with posterior wall thickness PW (r=0.380, P<0.001). No other observed variables including Galectin-3 and TIMP-1, correlated significantly with age or echocardiographic variables. In a comparison of patients with and without left ventricular hypertrophy, statistically significant differences were found only in LA (P<0.0001) and sST2 (P=0.004). In a multivariate logistic regression, sST2 and TIMP were independent predictors of left ventricular hypertrophy.
Conclusion: NT-proBNP level as a biomarker of cardiac remodeling correlated with parameters of LV diastolic function in patients with arterial hypertension. Soluble ST2 correlated with parameters of cardiac structure. Biomarkers sST2 and TIMP-1 were associated with left ventricular hypertrophy.
Keywords: arterial hypertension, biomarkers, cardiac structure, heart function, NT-proBNP, sST2, TIMP-1
Received: July 30, 2024; Revised: October 22, 2024; Accepted: October 23, 2024; Prepublished online: November 6, 2024
References
- Levy D, Larson MG, Martin G, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-62.
Go to original source...
- He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congetive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 2001;161:996.
Go to original source...
Go to PubMed...
- McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Heart Study. N Engl J Med 1971;285:1441-6.
Go to original source...
Go to PubMed...
- Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22:6A-13A.
Go to original source...
Go to PubMed...
- Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011;58:1733-40.
Go to original source...
Go to PubMed...
- Ganau A, Deveraux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-8.
Go to original source...
Go to PubMed...
- Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004;22:1597-604.
Go to original source...
Go to PubMed...
- Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction. The Framingham Heart Study. JAMA 2002;288:1252-9.
Go to original source...
Go to PubMed...
- Dhungana SP, Karki P, Lamsal M. Utility of N-terminal pro-brain natriuretic peptide in detecting diastolic dysfunction in asymptomatic hypertensive patients: comparison with echocardiography. J Cardiovasc Thorac Res 2019;11(1):14-18.
Go to original source...
Go to PubMed...
- Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of Plasma Brain and Atrial Natriuretic Peptides to Left Ventricular Geometric Patterns in Essential Hypertension. Am J Hypertension 1999;12:921-4.
Go to original source...
Go to PubMed...
- Hildebrandt P, Boesen M, Olsen M, Wachtell K, Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimsensions and prognosis. Eur J Heart Fail 2004;6:313-17.
Go to original source...
Go to PubMed...
- Wei P, Liu L, Wang X, Zong B, Liu X, Zhang M, Fu Q, Wang L, Cao B. Expression of soluble ST2 in patientswith essential hypertension and its relationship with left ventricular hypertrophy. ESC Heart Fail 2023;10(1):303-10. doi: 10.1002/ehf2.14147
Go to original source...
Go to PubMed...
- Wang Y, Yu Ch-Ch, Chiu FCh,Tsai ChT, Lai LP, Hwang JJ, Lin JL. Soluble ST2 as a Biomarker for Detecting Stable Heart Failure With a Normal Ejection Fraction in Hypertensive Patients. J Cardiac Fail 2013;19:163-8.
Go to original source...
Go to PubMed...
- AbouEzzeddine OF, McKie PM, Dunlay SM, Stevens SR, Felker GM, Borlaug BA, Chen HH, Tracy RT, Braunwald E, Redfield MM. Soluble ST2 in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 2017;6:e004382. doi: 10.1161/JAHA.116.004382
Go to original source...
Go to PubMed...
- Mitic VT, Sojanovic DR, Deljanin Ilic MZ, Stojanovic MM, Petrovic DB, Ignjatovic AM, Stefanovic NZ, Kocic GM, Bojanic VV. Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction. Tohoku J Exp 2020;250:233-42.
Go to original source...
Go to PubMed...
- Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B, André S, Crijns HJGM, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 2004;110(19):3121-8.
Go to original source...
Go to PubMed...
- Kempf T, Eden M, Strelau J, Naguib M, Willenbockel C, Tongers J, Heineke J, Kotlarz D, Xu J, Molkentin JD, Niessen HW, Drexler H, Wollert KC. The transforming growth factor beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006;98:351-60.
Go to original source...
Go to PubMed...
- Spinale FG. Matrix Metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res 2002;90:520-30.
Go to original source...
Go to PubMed...
- George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 2005;150:484-7.
Go to original source...
Go to PubMed...
- Patrick DM, Van Beusecum JP, Kirabo A. The role of inflammation in hypertension: novel concepts. Curr Opin Physiol 2021;19:92-8.
Go to original source...
Go to PubMed...
- Shankar A, Teppala S. Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease. J Am Soc Hypertens 2011;5(5):378-84.
Go to original source...
Go to PubMed...
- Omaygenc OM, Ozcan OU, Caakal B, Karaca O. Cystatin C and uncontrolled hypertension. Anatol J Cardiol 2020;24:309-15.
Go to original source...
Go to PubMed...
- Manzura M, Jayashree G. High sensitive C-reactive protein and ceruloplasmin in hypertension. Ind J Bas and Appl Med Res 2015;4(2):305-9.
- Lang RM, Badano LP, Mor-Avi V, Afialo J, Armstrong A, Ernande L. Recommendtions for cardiac chamber quantification by echocardiography in adults: an update from American Society of Echocardipgraphy and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70.
Go to original source...
Go to PubMed...
- Echocardiograhic Normal Ranges Meta-Analysis of the Left Heart Collaboration. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and Systolic Function: The Echo-NoRMAL Study. JACC Cardiovasc Imaging 2015;8:656-65. doi: 10.1016/j.jcmg.2015.02.014
Go to original source...
Go to PubMed...
- Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277-314.
Go to original source...
Go to PubMed...
- Parasuraman S, Walker S, Loudon BL, Gollop ND, Wilson AM, Lowery C, Frenneaux MP. Assessment of pulmonary artery pressure by echocardiography - A comprehensive review. Int J Cardiol Heart Vasc 2016;12:45-51. doi: 10.1016/j.ijcha.2016.05.011
Go to original source...
Go to PubMed...
- Fangyu LI, Hua HE. Assessing the Accuracy of Diagnostic Tests. Shanghai Arch Psychiatry 2018;30(3):207-12. doi: 10.11919/j.issn.1002-0829.218052
Go to original source...
Go to PubMed...
- Coutinho TC, Al-Omari M, Mosley TH, Kullo IJ. Biomarkes of left ventricular hypertrophy and remodeling in blacks. Hypertension 2011;58(5):920-5.
Go to original source...
Go to PubMed...
- Braunwald E. Biomarkers in heart failure. New Engl J Med 2008;358:2148-59.
Go to original source...
Go to PubMed...
- Tang W, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, Storrow AB, Wu AHB. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007;116:e99-e109.
Go to original source...
Go to PubMed...
- Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Di Nunzio D, Moncelli M, Iacoviello M, Scicchitano P. A Novel Cardiac Biomarker: ST2: A Review. Molecules 2013;18:15314-328.
Go to original source...
Go to PubMed...
- Coglianese EE, Larson MG, Vasa RS, Ho JE, Ghorbani A, McCabe EL, Cheng S, Fradley MG, Kretschman D, Gao W, O´Connor G, Wang TJ, Januzzi JL. Distribution and clinical correlates of the interleukin receptor family member sST2 in the framingham heart study. Clin Chem 2012;58:1673-81.
Go to original source...
Go to PubMed...
- Celic V, Majstorovic A, Pencic-Popovic B, Sljivic A, Lopez-Andres N, Roy I, Escribano E, Beunza M, Melero A, Floridi F, Magrini L, Marino R, Salerno G, Cardelli P, Di Somma S. Soluble ST2 Levels and Left Ventricular Structure and Function in Patients With Metabolic Syndrome. Ann Lab Med 2016;36:542-9.
Go to original source...
Go to PubMed...
- Hopps E, Presti R, Caimi G. Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment. Kidney Blood Press Res 2017;42:347-57.
Go to original source...
Go to PubMed...
- Dhingra R, Pencina MJ, Schrader P, Wang TJ, Levy D, Pencina K, Siwik DA, Colucci WS, Benjamin EJ, Vasan RS. Relations of Matrix Remodeling Biomarkers to Blood Pressure Progression and Incidence of Hypertension in the Community. Circulation 2009;119:1101-7.
Go to original source...
Go to PubMed...
- Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res 2007;30:959-63.
Go to original source...
Go to PubMed...
- Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, McClure CD, Spinale FG, Zile MR. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-96.
Go to original source...
Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.